Lovastatin
規格
75330-75-5CAS番号
616-212-7EC番号
[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoateIUPAC名
C24H36O5化学式
404.5 g/mol分子量
lovastatin; 75330-75-5; mevinolin; Mevacor; Altoprev; Mevlor; Sivlor; Altocor; MK-803; Monacolin K; Lovastatine; 6alpha-Methylcompactin; Lovastatina; Mevinacor; Lovastatinum [Latin]; 6-alpha-Methylcompactin; Lovastatinum; MK 803; DTXSID5020784; 9LHU78OQFD; NSC-758662; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate; L-154803; C10AA02; 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate; DTXCID50784; (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate; CHEBI:40303; 6-Methylcompactin; NSC633781; Lovastatinum (Latin); (1S-(1alpha(R*),3alpha,7beta,8beta(2S*,4S*),8abeta))-2-Methylbutanoic acid 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; (S)-2-Methylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one; 1,2,6,7,8,8a-Hexahydro-beta,delta-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutyoxy)-1-naphthaleneheptanoic acid delta-lactone; Butanoic acid, 2-methyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (1S-(1alpha(R*),3alpha,7beta,8beta(2S*,4S*),8abeta))-; 1 alpha-Isomer Lovastatin; 6 Methylcompactin; (1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxooxan-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate; MK803; alpha-Isomer Lovastatin, 1; ML-530B; Mevinacor 10; Mevinacor 40; ((1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-hydroxy-6-oxooxan-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl) (2S)-2-methylbutanoate; (S)-2-Methylbutyric acid, 8-ester with (4R,6R)-6-[2-[(1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl]ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one; Lovastatin, 1 alpha; RefChem:5964; (2S)-2-Methylbutanoic Acid, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl Ester; (8-(2-(4-hydroxy-6-oxooxan-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl) 2-methylbutanoate; 616-212-7; ((1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-hydroxy-6-oxooxan-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl) (2R)-2-methylbutanoate; Lovalord; Nergadan; Artein; Lovastatine [French]; Lovastatina [Spanish]; Lovalip; Hipovastin; Lovasterol; Cholestra; Closterol; Colevix; Hipolip; Lestatin; Lipivas; Lipofren; Lovastin; Lozutin; Paschol; Rodatin; Rovacor; Tecnolip; Teroltrat; Belvas; Lipdip; Taucor; butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, (2S)-; Lovastatin [USAN]; MLS000069585; Lovastatin (Standard); 6.alpha.-Methylcompactin; MSD 803; MFCD00072164; SMR000058779; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate; C24H36O5; (S)-(1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2-methylbutanoate; HSDB 6534; NCGC00023509-03; (1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (S)-2-methylbutanoate; Liposcler; 6 alpha-Methylcompactin; Rextat; Monakolin K; Lovastatin (Mevacor); (+)-mevinolin; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxo-tetrahydropyran-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate; Mevacor (TN); CHEMBL503; Lovastatin & Primycin; Lovastatin (USP/INN); SR-05000001880; UNII-9LHU78OQFD; Simvastatin EP Impurity E; BRN 3631989; Tancor; CCRIS 8092; Mevinacor;; Lipofren;; Nergadan;; Mevacor;; Lovastatin CRS; Monacolin K;; 1cqp; Lovastatin [USAN:USP:INN:BAN]; (2S)-2-METHYLBUTANOIC ACID (1S,3R,7S,8S,8AR)-1,2,3,7,8,8A-HEXAHYDRO-3,7-DIMETHYL-8-(2-((2R,4R)-TETRAHYDRO-4-HYDROXY-6-OXO-2H-PYRAN-2-YL)ETHYL)-1-NAPHTHALENYL ESTER; (2S)-2-Methylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (2S)-; Prestwick_819; CAS-75330-75-5; Mevinolin (lovastatin); LOVASTATIN [MI]; LOVASTATIN [INN]; Opera_ID_1578; Prestwick0_000516; Prestwick1_000516; Prestwick2_000516; Prestwick3_000516; Spectrum3_001873; Spectrum5_001294; Lovastatin (MK-803); LOVASTATIN [HSDB]; LOVASTATIN [VANDF]; EC 616-212-7; LOVASTATIN [MART.]; SCHEMBL3136; LOVASTATIN [USP-RS]; LOVASTATIN [WHO-DD]; US9115116, lovastatin; BIDD:PXR0113; BSPBio_000471; BSPBio_001265; BSPBio_003346; cid_53232; MLS001055358; MLS006011867; US9353061, Lovastatina; BIDD:GT0749; DivK1c_001032; SPECTRUM1503977; SPBio_002392; BPBio1_000519; GTPL2739; Lovastatin - Bio-X trade mark; MEGxm0_000398; orb1309414; orb3139800; LOVASTATIN [ORANGE BOOK]; ACon0_000534; ACon1_000390; BDBM34168; HMS503O05; HY-N0504R; KBio1_001032; KBio3_002848; LOVASTATIN [EP MONOGRAPH]; Simvastatin impurity, lovastatin-; NINDS_001032; GLXC-06458; HMS1569H13; HMS1792O07; HMS1923O13; HMS1990O07; HMS2089M06; HMS2093O03; HMS2096H13; HMS2236F07; HMS3039N16; HMS3259F10; HMS3268C03; HMS3403O07; HMS3412H19; HMS3676H19; HMS3713H13; HMS3884B03; LOVASTATIN [USP MONOGRAPH]; Pharmakon1600-01503977; ADVICOR COMPONENT LOVASTATIN; 2-Methyl-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester butanoic acid; ALBB-027272; HY-N0504; MK-803; LOVALIP; MEVACOR; MSK10235; Tox21_110888; Tox21_201475; Tox21_300268; BBL024473; CCG-39627; EBC-02080; NSC758662; NSC779704; s2061; SBB080686; STK801953; AKOS005267139; Lovastatin for peak identification CRS; Lovastatin; Simvastatin EP Impurity E; Tox21_110888_1; CS-1990; DB00227; FH24950; KS-1082; Mevinolin from Aspergillus sp., powder; NC00713; NSC 758662; NSC-633781; NSC-779704; IDI1_001032; NCGC00023509-04; NCGC00023509-05; NCGC00023509-06; NCGC00023509-07; NCGC00023509-08; NCGC00023509-09; NCGC00023509-10; NCGC00023509-11; NCGC00023509-13; NCGC00023509-14; NCGC00023509-16; NCGC00023509-23; NCGC00023509-25; NCGC00254157-01; NCGC00259026-01; AC-13961; BL164644; Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (2S)-; G226; SMR000673570; SBI-0051881.P002; CS-0694830; L0214; NS00000544; SIMVASTATIN IMPURITY E [EP IMPURITY]; EN300-52515; C07074; D00359; M02056; AB00052400-17; AB00052400_18; AB00052400_19; Mevinolin from Aspergillus sp., >=98% (HPLC); Q417740; SR-01000000123; SR-01000000123-3; SR-05000001880-1; SR-05000001880-2; BRD-K09416995-001-06-8; BRD-K09416995-001-21-7; BRD-K09416995-001-38-1; BRD-K09416995-001-39-9; BRD-K09416995-001-40-7; SIMVASTATIN IMPURITY, LOVASTATIN- [USP IMPURITY]; Z754931258; (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-8-(2-((4R,6R)-4-hydroxy-2-oxo-2H-pyran-6-yl)ethyl)-3,7-dimethylnaphtyl(S)-2-methylbutyrat; (S)-2-Methyl-butyric acid (1S,3R,7S,8S,8aR)-8-[2-((3R,5R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl ester; 1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl 2-methylbutanoate; 1S,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate; 8-[2-((2R,4R)-4-hydroxy-6-oxo(2H-3,4,5-trihydropyran-2-yl))ethyl](1S,7S,8S,3R, 8aR)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthyl (2S)-2-methylbutanoate; Butanoic acid, 2-methyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-- oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (1S-(1alpha(R*),3alpha,7beta,8beta(2S*,4S*),8abeta))-; BUTANOIC ACID, 2-METHYL-, 1,2,3,7,8,8A-HEXAHYDRO-3,7-DIMETHYL-8-(2-(TETRAHYDRO-4-HYDROXY-6-OXO-2H-PYRAN-2-YL)ETHYL)-1-NAPHTHALENYL ESTER, (1S-(1.ALPHA.(R*),3.ALPHA.,7.BETA.,8.BETA.(2S*,4S*),8.ALPHA..BETA.))-別名
Lovastatinを含む製品
로바이틴정(로바스타틴)로바타딘정(로바스타틴)(수출명:LovacTablet)로바콜정(로바스타틴)(수출용)TAUCOR 20 mgLOVASTATINA VIR 40 mg COMPRIMIDOS EFGLOVASTATINA VIR 20 mg COMPRIMIDOS EFGLOVASTATINA KERN PHARMA 40 mg COMPRIMIDOS EFGLOVASTATINA KERN PHARMA 20 mg COMPRIMIDOS EFGCOLESVIR 40 mg COMPRIMIDOSCOLESVIR 20 mg COMPRIMIDOSLOVASTATINA NORMON 40 mg COMPRIMIDOS EFGLOVASTATINA NORMON 20 mg COMPRIMIDOS EFG
1/6ページ
Lovastatinを販売する企業
CT
Công Ty Cổ Phần Dược Phẩm Tv.Pharm Viet NamCT
Công ty cổ phần dược phẩm WealpharViet Nam1/5ページ